Doctors Clinic

The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between January 1 and 31, 2026. The next update is scheduled for April 2026.

Announcement: Notice of intent to control zuranolone under the Controlled Drugs and Substances Act; Announcement: New clinical information resource on cannabis for medical purposes; PM update: Accutane, Epuris and Absorica LD (isotretinoin); Notice of authorization with conditions: Hyrnuo (sevabertinib): Notice of authorization with conditions: Ziihera (zanidatamab for injection); Medication Error Alert: Psyllium and the risk of choking

The intent of this notice is to clarify Health Canada’s expectations regarding the reporting of cases identified from the Canada Vigilance (CV) Adverse Reaction (AR) Online Database by MAHs. In particular, this notice replaces section 4.3 of the Reporting Adverse Reactions to Marketed Health Products – Guidance Document for Industry (2018) and the Notice to Industry (2020).

Physical activity levels among Canadians using a health equity lens; Child maltreatment in Canada: prevalence and gender differences among youth; Prosocial behaviour and happiness among children aged 6 to 11 years in Canada

test

test

The data presented in the Canada Vigilance Adverse Reaction Online Database has been updated and now includes information received by Health Canada up to October 31, 2025. The next update of data is scheduled for early March, 2026.

The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between December 1 and 31, 2025. The next update is scheduled for March 2026.

Content: Safety brief: Potential risks of radiofrequency microneedling; Safety brief: The use of some natural health products and the potential risk of hepatotoxicity; Notice of authorization with conditions: Wegovy (semaglutide)